~~<i id='8399669265'><strike id='8399669265'><tt id='8399669265'><pre id='8399669265'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：leisure time 2025-10-02 19:15:28 - browse：62

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA warns medical device makers about rise in fabricated data

focus

explore

hotspot

leisure time

Wikipedia

hotspot

Whatcausesourearstopopandwhataretheydoing,exactly?AlexHogan,MatthewOrr/STATTakingoffinanairplanealwa

WSS

Latest bird flu infection made farmworker sicker than earlier cases

Researchers tackle phage therapy hurdles for wider adoption

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment grows 7.1% to 33.4 million people

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

hotspot

explore

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Health insurers say they are turning to AI to cut costs, improve care

Medical leaders decry Supreme Court decision on affirmative action

Do more moles mean more problems? Not so, says new study

New air purifier tech could be key to improving indoor air quality

iTeos Therapeutics debuts first data on TIGIT

Dobbs anniversary: the lost opportunity of abortion as health care

Prosthetic arm enables patients to feel the objects they grip

Dobbs anniversary: the lost opportunity of abortion as health care

Abridge raises $150m as clinical notes automation market heats up

explore

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

In 'major milestone,' FDA approves first cell therapy for solid tumors

Stigma and the return of syphilis

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

New study raises questions about niacin and heart health

Prosthetic arm enables patients to feel the objects they grip

hotspot

leisure time

Wikipedia

hotspot